

ESMO Breast Cancer Virtual Congress 2021
Industry Satellite Symposium

What makes the difference in treating HR+, HER2- ABC?

6 May 2021 • 19:00–20:00 CEST

Meeting Objectives

- Review recent evidence on CDK4/6 and PI3Kα inhibitors in HR+, HER2-advanced breast cancer
- Provide expert insights on how tumor biology may influence treatment decisions in patients with HR+, HER2- advanced breast cancer
- Discuss current unmet needs and the future of HR+, HER2- advanced breast cancer

Faculty



Stephen Chia,
MD



Eva Ciruelos,
MD, PhD



Philippe Aftimos,
MD

Agenda

TIME	TITLE/TOPIC	FACULTY
	Opening remarks	Stephen Chia, MD
10 mins	OS data with CDK4/6i: what do the data tell us?	Stephen Chia, MD
10 mins	Treatment decision: how tumor biology can help	Eva Ciruelos, MD, PhD
10 mins	Discussion	Stephen Chia, MD Eva Ciruelos, MD, PhD Philippe Aftimos, MD
10 mins	PI3Kα inhibitors: addressing unmet needs through precision medicine in HR+, HER2- ABC <ul style="list-style-type: none">• From scientific breakthrough...• ...to clinical practice	Philippe Aftimos, MD Eva Ciruelos, MD, PhD
10 mins	Discussion	Stephen Chia, MD Eva Ciruelos, MD, PhD Philippe Aftimos, MD
10 mins	Live Q&A session	Stephen Chia, MD Eva Ciruelos, MD, PhD Philippe Aftimos, MD
	Closing remarks	Stephen Chia, MD

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.
This program and/or material was developed for use outside of the US, intended for non-US HCPs, and is to be used in accordance with local laws and regulations.